Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT-202
- Development stage
- Preclinical
- Lead developer
- Royaltechmed
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RT-202 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by Royaltechmed for the treatment of acute myeloid leukaemia (AML). The therapy is designed to target C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A), a type II transmembrane glycoprotein that is highly expressed on the surface of AML blasts and leukemic stem cells (LSCs) but is minimally expressed on normal hematopoietic stem cells. By specifically targeting CLL-1, RT-202 aims to induce the selective lysis of malignant cells while sparing healthy bone marrow progenitors, potentially offering a more targeted approach to treating AML and preventing disease relapse. The program is currently in the preclinical phase of development.
- Other names
- RT-202RT202RT 202
02
Targets
CLEC12A
Beyond the preview
Go deeper on RT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT-202.